{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:56Z","timestamp":1791912476069,"version":"4.3.4"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00538","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T19:20:03Z","timestamp":1594408803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":95,"title":["Novel Treatments in Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Deepak","family":"Menon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1756285615605700","article-title":"Future perspectives in target-specific immunotherapies of myasthenia gravis","volume":"8","author":"Dalakas","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","article-title":"The development and function of regulatory t cells","volume":"66","author":"Workman","year":"2009","journal-title":"Cell Mol Life Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin Rev Allergy Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against b-Cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory t cells in myasthenia gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol."},{"key":"B9","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of igG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/14728222.2014.877891","article-title":"Targeting the fc receptor in autoimmune disease","volume":"18","author":"Li","year":"2014","journal-title":"Expert Opin Ther Targets."},{"key":"B11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.neurol.2013.02.005","article-title":"The thymus in autoimmune myasthenia gravis: paradigm for a tertiary lymphoid organ","volume":"169","author":"Weiss","year":"2013","journal-title":"Rev Neurol (Paris)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M","article-title":"A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited","volume":"41","author":"Buttgereit","year":"1998","journal-title":"Arthr Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","article-title":"Advances in the understanding of the mechanism of action of iVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1385\/IR:33:2:103","article-title":"The complement system and innate immunity","volume":"33","author":"Charles","year":"2001","journal-title":"Immunobiology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1196\/annals.1405.009","article-title":"Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis","volume":"1132","author":"Christadoss","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of c3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve."},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1515\/revneuro-2014-0021","article-title":"Targeting complement system to treat myasthenia gravis","volume":"25","author":"Huda","year":"2014","journal-title":"Rev Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","article-title":"Complement therapeutics in autoimmune disease","volume":"10","author":"Thurman","year":"2019","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement deposition at the neuromuscular junction in seronegative myasthenia gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B25","unstructured":"Soliris"},{"key":"B26","unstructured":"Safety Tolerability and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis"},{"key":"B27","unstructured":"A Phase 3, Randomized Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Na\u00efve Adult Patients With Generalized Myasthenia Gravis | Clinical Research Trial Listing (Generalized Myasthenia Gravis | Myasthenia Gravis generalised)"},{"key":"B28","unstructured":"An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness"},{"key":"B29","unstructured":"A Study to Evaluate the Safety, Tolerability Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis"},{"key":"B30","unstructured":"A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis"},{"key":"B31","unstructured":"A Study of RVT-1401 in Myasthenia Gravis (MG) Patients"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology."},{"key":"B33","unstructured":"Therapy of Antibody-Mediated Autoimmune Diseases by Bortezomib (TAVAB)"},{"key":"B34","unstructured":"Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)"},{"key":"B35","unstructured":"Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases"},{"key":"B36","doi-asserted-by":"publisher","first-page":"159993","DOI":"10.1371\/journal.pone.0159993","article-title":"Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a Retrospective cohort study","volume":"11","author":"Bourque","year":"2016","journal-title":"PLoS ONE."},{"key":"B37","unstructured":"O.33Subcutaneous immunoglobulin in myasthenia gravis: results of a north american open label studyS125 PasnoorM BrilV LevineT TrivediJ SilvestriN PhadnisM 10.1016\/j.nmd.2019.06.316Neuromus Disord.292019"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","article-title":"Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial","volume":"89","author":"Beecher","year":"2017","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1196\/annals.1405.022","article-title":"Antisense treatment for myasthenia gravis","volume":"1132","author":"Sussman","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B40","unstructured":"Muscular Dystrophy AssociationFDA Approves Soliris to Treat Generalized Myasthenia Gravis2017"},{"key":"B41","unstructured":"FDAFDA Approves First Treatment for Neuromyelitis Optica Spectrum Disorder, A Rare Autoimmune Disease of the Central Nervous System2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-09770-y","article-title":"\u2018Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume-title":"J Neurol.","author":"Vissing","year":"2020"},{"key":"B45","unstructured":"Zilucoplan"},{"key":"B46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of aLXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS ONE."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2040620719874728","DOI":"10.1177\/2040620719874728","article-title":"Ravulizumab: a novel c5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"10","author":"Stern","year":"2019","journal-title":"Ther Adv Hematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in c5-inhibitor\u2013experienced adult patients with pNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1096\/fasebj.5.12.1916092","article-title":"Fc receptors and immunoglobulin binding factors","volume":"5","author":"Fridman","year":"1991","journal-title":"FASEB J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal fcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"The Journal of Immunology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces igGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of fcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of igG reduction in a first-in-Human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B57","unstructured":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)"},{"key":"B58","first-page":"1346","article-title":"Myasthenia gravis during pregnancy","volume":"58","author":"Chaudhry","year":"2012","journal-title":"Can Fam Physician."},{"key":"B59","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The fcRn inhibitor rozanolixizumab reduces human serum igG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"key":"B60","unstructured":"Phase 2 study shows rozanolixizumab is safe and effective PintoD Myasthenia Gravis News.2018"},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration","volume-title":"American Academy of Neurology Annual Meeting","author":"Collins","year":"2019"},{"key":"B62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0022-510x(91)90067-h","article-title":"Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro","volume":"102","author":"Birmanns","year":"1991","journal-title":"J Neurol Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1034\/j.1600-0404.2003.00209.x","article-title":"Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients","volume":"109","author":"Guillermo","year":"2004","journal-title":"Acta neurologica Scandinavica."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/WNL.0000000000007605","article-title":"Efgartigimod: a novel antibody depletion therapy in myasthenia gravis","volume":"92","author":"Guidon","year":"2019","journal-title":"Neurology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve."},{"key":"B66","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting b Cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jneuroim.2013.09.006","article-title":"Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients","volume":"264","author":"Kohler","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e939520","DOI":"10.4061\/2011\/939520","article-title":"B-Cell-Activating factor and autoimmune myasthenia gravis","volume":"2011","author":"Ragheb","year":"2011","journal-title":"Autoimmune Diseases."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/S0022-5223(03)00938-3","article-title":"The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated b-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer","volume":"126","author":"Okumura","year":"2003","journal-title":"The J Thor Cardiovasc Surg."},{"key":"B70","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review: rituximab in myasthenia gravis","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"key":"B72","unstructured":"High Efficacy of Rituximab for Myasthenia Gravis: A Comprehensive Nationwide Study in Austria"},{"key":"B73","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume-title":"JAMA Neurol","author":"Brauner","year":"2020"},{"key":"B74","unstructured":"BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JND-170294","article-title":"New pathways and therapeutic targets in autoimmune myasthenia gravis","volume":"5","author":"Behin","year":"2018","journal-title":"J Neuromusc Dise."},{"key":"B76","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting b Cells for myasthenia gravis therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neurovirol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights."},{"key":"B79","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs."},{"key":"B80","doi-asserted-by":"publisher","first-page":"26707","DOI":"10.1002\/mus.26707","article-title":"Refractory myasthenia gravis successfully treated with ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Muscle Nerve."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell\u2013activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle & Nerve."},{"key":"B82","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for baff develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med."},{"key":"B83","unstructured":"B-Cell-Activating Factor and Autoimmune Myasthenia Gravis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11926-012-0256-4","article-title":"Belimumab is approved by the fDA: what more do we need to know to optimize decision making?","volume":"14","author":"Horowitz","year":"2012","journal-title":"Curr Rheumatol Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.smim.2007.12.002","article-title":"Plasma cell development: from b-cell subsets to long-term survival niches","volume":"20","author":"Fairfax","year":"2008","journal-title":"Semin Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors \u2013 molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (VelcadeTM) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.100253910.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"24523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open."},{"key":"B90","doi-asserted-by":"publisher","first-page":"175628561772109","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe muSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2017.08.005","article-title":"ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response","volume":"311","author":"Liu","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.4049\/jimmunol.175.3.2018","article-title":"IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1","volume":"175","author":"Yang","year":"2005","journal-title":"J Immunol Baltim Md 1950"},{"key":"B93","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of iL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a New era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"CPB."},{"key":"B96","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in cAR t-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncol."},{"key":"B97","unstructured":"National Cancer InstituteTisagenlecleucel (Kymriah) Approved to Treat Some Lymphomas2018"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5727516","article-title":"Immunotherapy deriving from cAR-T cell treatment in autoimmune diseases","volume":"2019","author":"Chen","year":"2019","journal-title":"J Immunol Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/archneur.62.6.860","article-title":"Hematopoietic stem cell transplantation for multiple sclerosis","volume":"62","author":"Burt","year":"2005","journal-title":"Arch Neurol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e3290894","DOI":"10.1155\/2019\/3290894","article-title":"Review of the current knowledge on the role of stem cell transplantation in neurorehabilitation","volume":"2019","author":"Kamelska-Sadowska","year":"2019","journal-title":"BioMed Res Int."},{"key":"B101","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/jnnp-2017-316271","article-title":"Autologous haematopoietic stem cell transplantation for neurological diseases","volume":"89","author":"Burman","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B102","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3324\/haematol.2009.017038","article-title":"Stem cell transplantation for autoimmune diseases","volume":"95","author":"H\u00fcgle","year":"2010","journal-title":"Haematologica."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.3389\/fimmu.2018.02602","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers","volume":"9","author":"Malmegrim","year":"2018","journal-title":"Front Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia gravis treated with autologous hematopoietic stem cell transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.3389\/fimmu.2018.02056","article-title":"The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-Related diseases: a Systematic review","volume":"9","author":"Leyendecker","year":"2018","journal-title":"Front Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaneurol.2016.0191","article-title":"Treatment for refractory myasthenia gravis\u2014New lymphs for old","volume":"73","author":"Drachman","year":"2016","journal-title":"JAMA Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1586\/1744666X.2014.971757","article-title":"Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes","volume":"10","author":"Alabdali","year":"2014","journal-title":"Exp Rev Clin Immunol."},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume-title":"Cochr Datab Syst Rev","author":"Gajdos","year":"2012"},{"key":"B109","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology."},{"key":"B110","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/imt.13.146","article-title":"Subcutaneous igG in neurologic diseases","volume":"6","author":"Berger","year":"2014","journal-title":"Immunotherapy."},{"key":"B113","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/BTT.S25188","article-title":"Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases","volume":"6","author":"Kobrynski","year":"2012","journal-title":"Biologics."},{"key":"B114","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00019052-199912000-00014","article-title":"Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms","volume":"12","author":"Kaufer","year":"1999","journal-title":"Curr Opin Neurol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S25716","article-title":"New treatments for myasthenia: a focus on antisense oligonucleotides","volume":"7","author":"Angelini","year":"2013","journal-title":"Drug Des Devel Ther."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:21:09Z","timestamp":1723227669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":115,"alternative-id":["10.3389\/fneur.2020.00538"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00538","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"article-number":"538"}}